Evaluation of the safety profile of glucagon-like peptide-1 receptor agonists: a focus on thyroid cancer-related adverse events by using the European pharmacovigilance database.

Anatriello A, Liguori V, Pentella C, Zinzi A, Longo M, Caruso P, Maiorino MI, Esposito K, Capuano A

Pharmacological reports : PR28 May 2026

PMID42207473DOI10.1007/s43440-026-00864-4PepBankPUB-42207473

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

2 results from studies that gave the peptide. 2 results from people.

01HumanObservational studySafety outcome
In EudraVigilance reports, semaglutide had lower thyroid cancer-related adverse event reporting odds than tirzepatide.
In plain wordsIn patient safety reports, semaglutide was linked to lower thyroid cancer reporting odds than tirzepatide.
Peptide
Semaglutide
Outcome
DecreaseThyroid cancer adverse event reporting
Study
Homo sapiensn: not reported in source
Individual case safety reports from the EudraVigilance pharmacovigilance database
Comparator
tirzepatide
Outcome group
Adverse events · Cancer
Studied dose
Dose not stated
Measurements
ROR
0.54 ratio
semaglutide versus tirzepatide
Source sentences
Summary
Disproportionality analysis revealed that semaglutide had a lower probability of reporting thyroid cancer-related AEs than tirzepatide (ROR = 0.54, 95% CI 0.37-0.81, p < 0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
ICSRs reporting GLP-1 RAs (semaglutide, liraglutide, exenatide, lixisenatide, dulaglutide) or the dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide as suspected drugs were retrieved from the EudraVigilance (EV) database from 1st January 2022 to 26th September 2024.
Report a problemFND-4220747301
02HumanObservational studySafety outcome
In EudraVigilance reports, tirzepatide had higher thyroid cancer-related adverse event reporting odds than semaglutide.
In plain wordsIn patient safety reports, tirzepatide was linked to higher thyroid cancer reporting odds than semaglutide.
Peptide
Tirzepatide
Outcome
IncreaseThyroid cancer adverse event reporting
Study
Homo sapiensn: not reported in source
Individual case safety reports from the EudraVigilance pharmacovigilance database
Comparator
semaglutide
Outcome group
Adverse events · Cancer
Studied dose
Dose not stated
Measurements
ROR
0.54 ratio
semaglutide versus tirzepatide (tirzepatide is the comparator; inverse not reported)
Source sentences
Summary
Disproportionality analysis revealed that semaglutide had a lower probability of reporting thyroid cancer-related AEs than tirzepatide (ROR = 0.54, 95% CI 0.37-0.81, p < 0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
ICSRs reporting GLP-1 RAs (semaglutide, liraglutide, exenatide, lixisenatide, dulaglutide) or the dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide as suspected drugs were retrieved from the EudraVigilance (EV) database from 1st January 2022 to 26th September 2024.
Report a problemFND-4220747302

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In EudraVigilance analysis of GLP-1 agents including dulaglutide, therapeutic-group stratification identified no significant thyroid cancer reporting signals.
In plain wordsDatabase analysis of GLP-1 agents, including dulaglutide, found no significant thyroid cancer reporting signals across therapeutic groups.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeStratified thyroid cancer reporting signals
Study
Homo sapiensn: not reported in source
Individual case safety reports from the EudraVigilance pharmacovigilance database
Outcome group
Adverse events · Cancer
Source sentences
Summary
whereas sensitivity analysis revealed no significant signals across stratified therapeutic groups.
1 context sentence(design, population, supporting numbers)
Summary · context
ICSRs reporting GLP-1 RAs (semaglutide, liraglutide, exenatide, lixisenatide, dulaglutide) or the dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide as suspected drugs were retrieved from the EudraVigilance (EV) database from 1st January 2022 to 26th September 2024.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4220747303
04HumanNot a test of Liraglutide aloneObservational studySafety outcome
In EudraVigilance analysis of GLP-1 agents including liraglutide, therapeutic-group stratification identified no significant thyroid cancer reporting signals.
In plain wordsDatabase analysis of GLP-1 agents, including liraglutide, found no significant thyroid cancer reporting signals across therapeutic groups.
Peptide
Liraglutide
Outcome
No significant changeStratified thyroid cancer reporting signals
Study
Homo sapiensn: not reported in source
Individual case safety reports from the EudraVigilance pharmacovigilance database
Outcome group
Adverse events · Cancer
Source sentences
Summary
whereas sensitivity analysis revealed no significant signals across stratified therapeutic groups.
1 context sentence(design, population, supporting numbers)
Summary · context
ICSRs reporting GLP-1 RAs (semaglutide, liraglutide, exenatide, lixisenatide, dulaglutide) or the dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide as suspected drugs were retrieved from the EudraVigilance (EV) database from 1st January 2022 to 26th September 2024.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4220747304
05HumanNot a test of Semaglutide aloneObservational studySafety outcome
In EudraVigilance analysis of GLP-1 agents including semaglutide, therapeutic-group stratification identified no significant thyroid cancer reporting signals.
In plain wordsDatabase analysis of GLP-1 agents, including semaglutide, found no significant thyroid cancer reporting signals across therapeutic groups.
Peptide
Semaglutide
Outcome
No significant changeStratified thyroid cancer reporting signals
Study
Homo sapiensn: not reported in source
Individual case safety reports from the EudraVigilance pharmacovigilance database
Outcome group
Adverse events · Cancer
Source sentences
Summary
whereas sensitivity analysis revealed no significant signals across stratified therapeutic groups.
1 context sentence(design, population, supporting numbers)
Summary · context
ICSRs reporting GLP-1 RAs (semaglutide, liraglutide, exenatide, lixisenatide, dulaglutide) or the dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide as suspected drugs were retrieved from the EudraVigilance (EV) database from 1st January 2022 to 26th September 2024.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4220747305
06HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In EudraVigilance analysis of GLP-1 agents including tirzepatide, therapeutic-group stratification identified no significant thyroid cancer reporting signals.
In plain wordsDatabase analysis of GLP-1 agents, including tirzepatide, found no significant thyroid cancer reporting signals across therapeutic groups.
Peptide
Tirzepatide
Outcome
No significant changeStratified thyroid cancer reporting signals
Study
Homo sapiensn: not reported in source
Individual case safety reports from the EudraVigilance pharmacovigilance database
Outcome group
Adverse events · Cancer
Source sentences
Summary
whereas sensitivity analysis revealed no significant signals across stratified therapeutic groups.
1 context sentence(design, population, supporting numbers)
Summary · context
ICSRs reporting GLP-1 RAs (semaglutide, liraglutide, exenatide, lixisenatide, dulaglutide) or the dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide as suspected drugs were retrieved from the EudraVigilance (EV) database from 1st January 2022 to 26th September 2024.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4220747306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 6Current
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 5
22 Oct 2026, 02:25 UTC
Study results updated
Versions 2 to 4
21 Oct 2026, 18:59 UTC
The same notice was added 3 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.